Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 37 results for bisphosphonates

  1. Abaloparatide for treating osteoporosis after menopause (TA991)

    Evidence-based recommendations on abaloparatide (Eladynos) for treating osteoporosis after menopause in women, trans men and non-binary people with a very high risk of fracture.

  2. Myeloma: diagnosis and management (NG35)

    This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.

  3. Patient decision aids

    conditions Type 2 diabetes: agreeing my blood glucose (HbA1c) target Bisphosphonates for treating osteoporosis Digestive tract...

  4. [NICE] recommends research into the long-term effects of bisphosphonates on bone quality, given the inhibitory effects on bone resorption of these drugs.

    Question [NICE] recommends research into the long-term effects of bisphosphonates on bone quality, given the inhibitory effects on bone...

  5. Bisphosphonates for the prevention of bone disease:- What is the effectiveness of monthly zoledronic acid given indefinitely compared with zoledronic acid given for a fixed duration in patients with myeloma?

    Recommendation ID NG35/5 Question Bisphosphonates for the prevention of bone disease:- What is the effectiveness of monthly zoledronic

  6. Non-bisphosphonates for treating osteoporosis [ID901]

    Discontinued [GID-TA10072]

  7. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184)

    This guideline covers investigating and managing gastro-oesophageal reflux disease (GORD) and dyspepsia in people aged 18 and over. It aims to improve the treatment of GORD and dyspepsia by making detailed recommendations on Helicobacter pylori eradication, and specifying when to consider laparoscopic fundoplication and referral to specialist services.

  8. Tocilizumab for treating giant cell arteritis (TA518)

    Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.

  9. Radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastases (IPG759)

    Evidence-based recommendations on radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastases. This involves inserting a needle-like probe containing an electrode into the spinal metastases. This produces an electrical current that aims to relieve pain and other symptoms.

  10. Radiofrequency ablation for palliation of painful spinal metastases (IPG758)

    Evidence-based recommendations on radiofrequency ablation for palliation of painful spinal metastases. This involves inserting a needle-like probe containing an electrode into the spinal metastases. This produces an electrical current that aims to relieve pain and other symptoms.

  11. What are the optimal management strategies for primary hyperparathyroidism during pregnancy?

    cinacalcet should not be offered during pregnancy. They also agreed that bisphosphonates are potentially harmful for the mother and the...

  12. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)

    Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases in adults.

  13. Stopping preventive medicines:- What is the clinical and cost effectiveness of stopping preventive medicines in people with multimorbidity who may not benefit from continuing them?

    The review found several randomised controlled trials of stopping bisphosphonates (although not clearly in populations with...

  14. Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates (ES15)

    This evidence summary has been updated and replaced by NICE guideline NG101.

  15. Eating disorders: recognition and treatment (NG69)

    This guideline covers assessment, treatment, monitoring and inpatient care for children, young people and adults with eating disorders. It aims to improve the care people receive by detailing the most effective treatments for anorexia nervosa, binge eating disorder and bulimia nervosa.